Summary of the Conference Call for Dong-E E-Jiao Company Overview - The company discussed is Dong-E E-Jiao, a prominent player in the traditional Chinese medicine sector, particularly known for its E-Jiao products. Key Points and Arguments Financial Performance and Growth - The company maintained double-digit growth in the first three quarters of 2025, with inventory at historically low levels, and terminal sales performing better than expected since December 2025 [2][3] - The main business, including E-Jiao blocks, syrups, powders, and health products, is expected to achieve over double-digit growth in 2026 [2][6] - The company has a high-quality dividend attribute, maintaining a long-term payout ratio of 90% to 100%, with stable cash flow and accounts receivable management [2][5] Inventory and Sales Dynamics - The company has been actively reducing accounts receivable and inventory levels since the second quarter of 2025, leading to improved cash flow quality [3] - Since December 2025, terminal sales have shown significant improvement, particularly for the unique E-Jiao syrup, driven by reimbursement policies and strong brand pricing power [3][4] Strategic Initiatives - The "Opening Red" initiative for 2026 aims to enhance operational certainty by aligning channel delivery with sales, especially in a low inventory context [4] - The OTC channel currently covers approximately 80,000 pharmacies, with a future target of over 200,000, indicating significant growth potential [2][9] Product Development and Market Expansion - The company is expanding its male health product line through acquisitions to secure raw material supply and mitigate cost volatility [7][8] - The E-Jiao syrup is being promoted in hospitals, particularly for cancer patients, with substantial growth potential due to its inclusion in treatment guidelines [12] Online and Offline Sales Strategies - The company is cautious about new online sales strategies but is exploring collaborations with major platforms like JD.com to enhance online sales [13] - The product pricing is positioned in the mid-to-high range, with seasonal demand variations noted, particularly stronger in winter and spring [10][11] Regional Market Insights - Current market penetration is highest in Shandong and the East and North China regions, with lower penetration in areas like Guangdong and Sichuan, indicating room for growth [9] Additional Important Insights - The company’s focus on maintaining a robust cash flow and dividend structure positions it as a high-quality dividend stock, even while pursuing growth [5] - The strategic emphasis on academic promotion for E-Jiao syrup in hospitals highlights the company's commitment to expanding its market reach and enhancing product credibility [12]

Core Insights - The health industry in Liaocheng is a key emerging sector aimed at improving public welfare and driving economic transformation, focusing on pharmaceuticals, health foods, and medical devices [1][2] Group 1: Industry Development - Liaocheng's health industry aims to transition from "single-point breakthroughs" to "cluster collaboration" and from "traditional manufacturing" to "high-end intelligent manufacturing" by 2025 [1] - The city has 52 enterprises in the health industry, with a projected output value of 11.45 billion yuan in 2025, a year-on-year increase of 9.8%, and total profits of 2.03 billion yuan, up 13.2% [1] - The East A Ejiao and Guancounty Ganoderma industry clusters have been recognized as provincial-level health industry clusters, contributing to the city's inclusion in the provincial "Top Ten Industries" reserve [1] Group 2: Brand Development - A "1+N" brand system is being established, led by a public brand to promote multiple product brands, enhancing competitiveness [2] - The "Nine Lotus Flowers Ai" brand is being developed, with over 100 products and a comprehensive service network for moxibustion therapy [2] - The "Ai·Man Water City" brand has been launched to promote the health industry and enhance overall vitality [2] Group 3: Upgrading Traditional Brands - Dong'e Ejiao holds a 45% market share in the domestic market for Ejiao blocks, with its products recognized nationally and internationally [3] - Guancounty's Ganoderma accounts for 50% of national production and 60% of trading volume, maintaining a top-three brand value for three consecutive years [3] - The local company Qu Zhongzhou Biotechnology has over 13,000 stores globally, expanding into the beauty sector [3] Group 4: Brand Integration - The integration of brand building across the supply chain is emphasized to enhance collaboration between research, production, and sales [4] - A service system for technology transfer and commercialization is being established, involving experts and research centers [4] Group 5: Service Ecosystem - A comprehensive service system is being developed to support brand growth, including financial assistance and market cultivation [6] - The establishment of 13 key industrial parks is underway to provide standardized services for brand enterprises [6] - The implementation of local food safety standards for Ganoderma is being promoted to enhance brand credibility [6] Group 6: Future Planning - Future actions will focus on enhancing brand quality, promoting industrial collaboration, and expanding the international reach of traditional Chinese medicine [7] - The "Ai·Man Water City" public brand will be prioritized, and efforts will be made to integrate into national development strategies [7] - Plans to promote traditional Chinese medicine internationally through initiatives like the "Belt and Road" strategy are in place [7]

Core Viewpoint - The acquisition and evolution of the direct selling license by Dong'e Ejiao reflect not only the strategic choices of a single enterprise but also the profound changes in the industry from institutional arbitrage to value return over the past decade [1]. Group 1: Institutional Foundation - The issuance of the direct selling management regulations in 2005 marked the beginning of the legal framework for the direct selling industry in China, distinguishing between legal direct selling and illegal pyramid schemes [3]. - Dong'e Ejiao's direct selling license approval in 2015 occurred during a critical transition period for the industry, characterized by a shift from chaotic growth to regulated operations [3]. - The rigorous qualification process for obtaining a direct selling license underscores its significance as a testament to a company's brand reputation, product quality, and management system [3]. Group 2: Strategic Choices - Dong'e Ejiao entered the direct selling sector due to its need to diversify sales channels, as it faced a decline in revenue from traditional distribution methods [6]. - The direct selling model aligns well with the characteristics of Dong'e Ejiao's products, which require in-depth explanation and have clear repurchase cycles, making it suitable for face-to-face health consultations [6]. - The direct selling approach allows Dong'e Ejiao to enhance profitability while providing consumers with more accessible pricing, thus creating a win-win situation [6]. Group 3: Endowment Support - Dong'e Ejiao's unique brand heritage and ongoing technological innovation are key factors that enable its success in the direct selling arena [7]. - The company has established significant assets, including a national engineering research center and participation in the formulation of national pharmacopoeia standards, which bolster its confidence in entering the direct selling market [7]. - Dong'e Ejiao's strategic shift towards technology-driven growth has led to increased R&D investment, reaching 210 million yuan in 2024, a 27.63% increase year-on-year [7]. Group 4: Industry Changes - Over the past decade, the direct selling industry in China has transitioned from a focus on license acquisition to a more rational return to the essence of the industry [11]. - The industry has seen a decline in growth rates, with 13 licensed companies suspending or abandoning their direct selling operations between 2023 and 2024 [11]. - The future of direct selling is expected to evolve into a model centered on technology empowerment and community interaction, emphasizing the importance of creating irreplaceable customer value [11]. Group 5: Rational Examination - Despite obtaining the direct selling license, Dong'e Ejiao has not rapidly expanded its direct selling business, reflecting a cautious approach influenced by various external factors [14]. - The company recognizes the dual-edged nature of the direct selling model and has chosen to prioritize brand reputation over immediate sales growth [14]. - The strategic value of the direct selling license lies in its potential to facilitate deeper consumer engagement and future business innovations, particularly in the context of increasing health awareness [15]. Conclusion - The ten-year journey of Dong'e Ejiao's direct selling license represents a significant period of maturation for the Chinese direct selling industry and highlights the balance between institutional benefits and corporate endowments [17]. - The direct selling license serves as a baseline for compliant operations, a testament to brand credibility, and a reflection of the industry's return to value [17].

Core Viewpoint - Dong'e Ejiao plans to invest 1.485 billion yuan in a health consumer goods industrial park, marking one of its largest single investments in recent years [1][3] Group 1: Investment Details - The investment includes 1.421 billion yuan for fixed assets and 64 million yuan for liquidity support [1] - The project will cover an area of 406,800 square meters with a construction area of approximately 151,100 square meters, and is expected to take 22 months to complete [3] - This investment aligns with the company's "1238" strategy, which aims to develop a dual-driven growth model of pharmaceuticals and health consumer goods [3] Group 2: Business Strategy - The health consumer goods sector is characterized by diverse demand and rapid product iteration, necessitating higher standards for R&D, quality, and agile supply chains [3] - The existing industrial park faces limitations in expansion and capacity bottlenecks, prompting the need for new facilities to meet the fast-paced development of health consumer goods [3] - The new investment is seen as a strategic move to capitalize on the growing health industry and the trend of "younger health consumption" [3] Group 3: Financial Implications - The investment will consume a significant portion of the company's cash reserves, which stood at approximately 8.2 billion yuan as of the end of Q3 last year [6] - The shift towards heavier asset allocation may lead to a decline in fixed asset turnover during the construction phase, potentially impacting short-term profitability [6] - As of February 11, the company's stock price was 55.44 yuan, with a market capitalization of 35.7 billion yuan, reflecting an 18% decline over the previous year [6] Group 4: Market Competition - Investors express mixed opinions on the investment, with concerns about the impact on the company's balance sheet and liquidity [4] - Competitors in the health consumer goods space include Kunming Pharmaceutical, Yunnan Baiyao, and others, which may pose challenges for Dong'e Ejiao in achieving expected performance [7]

Core Viewpoint - Dong-E E-Jiao has confirmed its absence from the current bull market, with a year-to-date decline of 18% as of December 22, 2025. The company needs to identify new growth points, such as E-Jiao paste, male products, and international expansion, to regain momentum [1][12][13]. Stock Performance - As of December 22, 2025, Dong-E E-Jiao's stock closed at 49.25 yuan, reflecting a total market capitalization of 31.72 billion yuan. The stock has seen an 18% decline since the beginning of the year, contrasting sharply with the overall A-share market, where over 4,300 stocks recorded positive gains [2][14]. - The company has initiated a share buyback plan, intending to use 100 million to 200 million yuan to repurchase shares at a maximum price of 72.08 yuan per share. This is expected to involve the repurchase of approximately 138,730 to 277,470 shares, representing 0.22% to 0.43% of the total share capital [2][15]. Dividend Policy - Dong-E E-Jiao plans to distribute a cash dividend of 12.69 yuan per 10 shares, totaling approximately 817 million yuan, which indicates a high payout ratio. From 2020 to 2024, the company has consistently maintained a high dividend payout ratio, with a total cash dividend of 1.96 billion yuan in 2020, increasing to 15.55 billion yuan in 2024 [3][15][16]. Historical Context - Dong-E E-Jiao was once regarded as the "Moutai of medicine," experiencing a long-term bull market. However, after a series of price increases that led to a disconnect between product pricing and consumer demand, the company faced significant challenges, including a net profit loss of 455 million yuan in 2019 [4][18]. - The leadership transition from Qin Yufeng to Gao Dengfeng in 2020 marked a shift in strategy, with a renewed focus on E-Jiao paste, which has seen significant sales growth due to favorable policy changes [6][19][20]. Recent Developments - The company has launched new products targeting male consumers, such as the "Royal Weichang 1619" brand, and has made strategic acquisitions in the male health supplement sector [9][22]. - Dong-E E-Jiao is also expanding its international presence, having acquired Huaren Pharmaceutical Trading (Hong Kong) Co., Ltd. and established partnerships in Southeast Asia, although overseas revenue remains a small portion of total income [10][24].

Core Viewpoint - Dong'e Ejiao plans to repurchase A-shares with a total fund of between 100 million and 200 million yuan, marking the first share buyback and cancellation since its listing, aimed at enhancing investor confidence and recognizing the company's intrinsic value [1][2]. Group 1: Share Buyback Details - The repurchase price ceiling is set at 72.08 yuan per share, which is 150% of the average trading price over the previous 30 trading days [1]. - The estimated number of shares to be repurchased ranges from 1.3873 million to 2.7747 million, accounting for 0.22% to 0.43% of the current total share capital of 643,976,824 shares [1]. - The buyback period will last up to 12 months from the date of shareholder approval, with the board having the discretion to adjust the plan based on market conditions [1]. Group 2: Financial Position - As of September 30, 2025, Dong'e Ejiao's total assets are 12.749 billion yuan, with equity attributable to shareholders at 9.948 billion yuan and current assets at 9.823 billion yuan [2]. - The maximum repurchase amount of 200 million yuan represents only 1.57% of total assets, 2.01% of equity, and 2.04% of current assets, indicating a minimal impact on the company's financial health [2]. - The company asserts that the buyback will not significantly affect its daily operations, financial status, or future development [2]. Group 3: Business Performance and Strategy - Dong'e Ejiao reported a revenue of 4.766 billion yuan for the first three quarters of 2025, a year-on-year increase of 4.41%, with a net profit of 1.274 billion yuan, reflecting a growth of 10.53% [2]. - The company has maintained a high cash dividend policy, ranking first in the cash dividend payment rate among listed companies, with cumulative dividends exceeding 10 billion yuan since its listing [3]. - In 2025, Dong'e Ejiao made significant acquisitions, including a 70% stake in Ma Ji Pharmaceutical and an 80% stake in Alashan Corgoni Group, aiming to expand its product offerings in the male health supplement market [3].

Core Viewpoint - Dong'e Ejiao plans to repurchase shares worth 100 million to 200 million yuan, marking its first share buyback since listing, aimed at enhancing shareholder value through share cancellation and improving financial metrics [1] Group 1: Share Buyback and Financial Strategy - The repurchased shares will be used for capital reduction, directly enhancing earnings per share and return on equity [1] - Since 2025, Dong'e Ejiao's total dividends and buyback amounts have exceeded 1.8 billion yuan, showcasing a strong commitment to shareholder returns [1] - The company has maintained a high cash dividend ratio, with cumulative dividends surpassing 10 billion yuan, positioning it favorably within the consumer sector and A-share market [1] Group 2: Financial Performance - In the first three quarters of this year, Dong'e Ejiao reported a net cash flow from operating activities greater than 1, supporting its ongoing dividend and buyback initiatives [2] - The company achieved a revenue of 1.716 billion yuan in Q3, reflecting an 8.5% year-on-year increase, and a net profit of 456 million yuan, up 10.27% [2] - The product portfolio includes core items like Ejiao blocks and compound Ejiao syrup, with a diversified product system driving growth [2] Group 3: Market and Industry Trends - The recovery of the pharmacy channel and the end of industry adjustments provide a favorable sales environment for Dong'e Ejiao [2] - The company has expanded its online sales through e-commerce and live streaming, increasing its revenue share from digital channels [3] - National policies promoting consumption are expected to benefit the food, beverage, and health sectors, positioning Dong'e Ejiao to capitalize on demand growth [3] - Stable medical insurance and centralized procurement policies create a supportive environment for traditional Chinese medicine companies, enhancing market opportunities for Dong'e Ejiao [3]

Core Viewpoint - Dong'e Ejiao Co., Ltd. has announced a significant stock buyback plan of 100-200 million yuan, marking its first-ever share repurchase and cancellation, aimed at enhancing earnings per share and reflecting confidence in future growth [2][3] Group 1: Shareholder Return and Financial Performance - The company has maintained a high cash dividend policy since its listing, with cumulative dividends exceeding 10 billion yuan and a consistent 100% payout ratio, showcasing its strong cash flow and commitment to shareholder interests [2][3] - The stock buyback plan is expected to improve key financial metrics such as earnings per share and return on equity, contributing to a total shareholder return exceeding 1.8 billion yuan by 2025 through a combination of high dividends and share repurchase [3] - Dong'e Ejiao's third-quarter report indicates a stable cash flow with a net cash flow from operating activities greater than 1, supporting both dividends and buybacks, which highlights the sustainability of its shareholder returns [4] Group 2: Market Position and Industry Context - The company is experiencing a notable trend of shareholder concentration, with a slight decrease in the number of shareholders, indicating a narrowing of market divergence and a potential signal for long-term investors [4][5] - Despite the industry being in a recovery phase, Dong'e Ejiao has shown approximately 10% growth in revenue and net profit for the first three quarters, with a gross margin of 73.69%, reflecting strong operational performance [4][6] - The company is well-positioned in the herbal medicine sector, benefiting from brand strength and product barriers, with a diversified product matrix that includes core products like Ejiao blocks and compound Ejiao syrup [6][7] Group 3: Policy Environment and Future Outlook - Recent consumer stimulus policies and a more favorable environment for traditional Chinese medicine are expected to boost demand for Dong'e Ejiao's products, enhancing its growth prospects [7][8] - The easing of price pressure from centralized procurement policies is likely to benefit the company, allowing it to capture a larger market share and improve profitability [7] - Dong'e Ejiao is anticipated to leverage its first-mover advantage in the recovery of the consumer sector, positioning itself as a strong candidate for investment as market opportunities emerge [8]

Core Viewpoint - Overall, the company achieved an operating income of 4.766 billion yuan in the first three quarters, a year-on-year increase of 10.10%, and a net profit attributable to shareholders of 1.274 billion yuan, a year-on-year increase of 10.58%, demonstrating resilient growth amid external pressures [1][3] Financial Performance - In the first three quarters of 2025, the company reported an operating income of 4.766 billion yuan, a year-on-year increase of 4.41%, and a net profit attributable to shareholders of 1.274 billion yuan, a year-on-year increase of 10.53% [2][3] - The company’s net profit after deducting non-recurring items was 1.155 billion yuan, reflecting a year-on-year increase of 8.23% [2][3] - In Q3 alone, the company achieved an operating income of 1.716 billion yuan, a year-on-year increase of 8.50%, and a net profit of 456 million yuan, a year-on-year increase of 10.29% [3] Product Performance - The company’s core product, Ejiao and its series, is expected to maintain stable growth, with a focus on precise marketing and digital promotion [4] - The compound Ejiao syrup is projected to continue its steady growth due to a comprehensive brand strategy [4] - The company is actively constructing a second growth curve through the promotion of new product lines, including "Royal Weichang 1619" and others, which are expected to contribute positively to future performance [4][5] Strategic Outlook - The company is focusing on the "Growth and Breakthrough" management theme and aims to effectively implement the "1238" strategy [5] - The brand strength of Ejiao is expected to continue growing, contributing to stable product growth [5] - The company is also enhancing its marketing strategies and product offerings to ensure long-term healthy development [7] Profitability and Financial Metrics - The comprehensive gross profit margin for the first three quarters was 73.69%, an increase of 3.33 percentage points year-on-year [6] - The sales expense ratio decreased by 0.65 percentage points to 35.17%, indicating effective cost control [6] - The research and development expense ratio increased by 1.09 percentage points to 3.05%, reflecting a commitment to innovation [6] Earnings Forecast - The company is projected to achieve operating revenues of 6.663 billion yuan, 7.622 billion yuan, and 8.745 billion yuan for the years 2025 to 2027, with net profits of 1.773 billion yuan, 2.067 billion yuan, and 2.407 billion yuan respectively [7]

Core Viewpoint - The company demonstrated a healthy development trend in the first three quarters of 2025, with steady growth in core businesses and optimized R&D investment and expense control [12]. Financial Performance - In the first three quarters, the company achieved an operating income of 4.766 billion yuan, a year-on-year increase of 10.10% [1] - The net profit attributable to shareholders reached 1.274 billion yuan, up 10.58% year-on-year [1] - The net cash flow from operating activities was 1.31 billion yuan, with a basic earnings per share of 1.9781 yuan, reflecting a 10.35% increase [1] - The gross profit margin improved by 3.33 percentage points to 73.69%, driven by stable growth in core product lines and a focus on high-margin categories [1] Cost Management - The company maintained reasonable control over sales and management expenses, with R&D expenses increasing by 62.29% to 145 million yuan, emphasizing the importance of technological innovation and long-term competitiveness [1][2]. Product Performance - The core product matrix continued to perform well, with significant growth in the sales of Ejiao blocks, compound Ejiao syrup, and Taohua Ji Ejiao cake, further consolidating market share [4][5] - Ejiao blocks maintained a leading position in the OTC market, while compound Ejiao syrup gained recognition as a popular product in both hospital and retail channels [5] - The Taohua Ji Ejiao cake successfully attracted female consumers through product innovation and marketing strategies [5] Market Expansion - The company is actively targeting the silver economy and men's health sectors, with plans to innovate product forms and expand into the middle-aged and elderly markets [7] - The men's health product line includes unique formulations aimed at addressing common health issues, positioning the company for future growth [7] Brand Value - The company was recognized for its brand value, ranking 11th on the 2025 Health China Brand Value List with a brand value of 19.43 billion yuan [8] - It also received accolades for its innovative marketing strategies and was listed among the top 100 most valuable Chinese brands [8] Sustainable Development - The company is committed to sustainable practices, including agricultural development and ecological protection, which earned it the title of "Most Socially Responsible Listed Company" at the 2025 Phoenix Star Awards [9] Strategic Partnerships - The partnership with China Resources Group enhances the company's strategic transformation and ecological construction, facilitating investment in traditional Chinese medicine and international market exploration [11] - The establishment of a 1 billion yuan pharmaceutical industry investment fund aims to support innovative projects in the health sector [11] Future Outlook - The company is well-positioned for future growth with its strategic focus on the silver economy and men's health, alongside the support from its strategic partner, which will enhance its competitive edge in the traditional Chinese medicine market [12]